Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relapse-prevention study of Lu AA21004 in generalized anxiety disorder
2008-001673-15Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in generalized anxiety disorder (GAD) (3 arms), sponsored by Lundbeck. Primary endpoint: Time to relapse. Started Jul 2008; status: completed.
02
Drugs
vortioxetine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on 2008-001673-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001673-15.